Pure Bioscience Inc - PURE STOCK NEWS

PURE Bioscience reported its fiscal Q3 2024 financial results, highlighting a net product sales increase to $440,000 from $406,000 YoY, and a reduced net loss of $857,000 from $876,000 YoY. For the nine months ending April 30, 2024, net product sales were up to $1,483,000 from $1,269,000 YoY, with net loss decreasing to $2,594,000 from $2,929,000 YoY. The company is transitioning from a direct sales model to a distributor model, developing new pricing agreements, boosting social media engagement by 167%, and increasing followers by 70%. They continue to participate in trade shows and expand R&D efforts, focusing on food safety and environmental sustainability in industries like dairy and animal health.

PURE Bioscience, Inc. appointed Darin Zehr to its Board of Directors, effective May 1, 2024. Zehr, with extensive experience in the food industry, joins as an independent director and will serve on PURE's Audit and Compensation Committees. He previously worked at Kraft Foods for 22 years and is currently the General Manager of Commercial Food Sanitation Zehr holds a Bachelor of Science degree in Chemistry and brings valuable insights to PURE's Board.

PURE Bioscience reports financial results for the fiscal second quarter, highlighting net product sales, net loss, and business developments. Despite a decrease in sales, the company aims to expand its footprint in the food industry through brand advertising, trade shows, distributor focus, and continued innovation.

PURE Bioscience, Inc. (PURE) reported fiscal first quarter financial results, with net product sales of $718,000, a net loss of $735,000, and a net loss per share of ($0.01). The company's sales initiatives are paying off, with increased revenue and a customer-focused approach. The team is leveraging decades of combined experience and working on innovative solutions to enhance sanitation processes using IoT, SaaS, and automation.

PURE Bioscience reports financial results for fiscal year 2023, with net product sales of $1,871,000 and a net loss of ($4.0 million). Customer acceptance of SDC solutions in the food processing industry has increased, and the company has developed new applications for PURE Hard Surface. The company has attended conferences and trade shows to increase brand awareness and is working on marketing materials and website modifications. The CEO sees the increase in Q4 revenue as a turning point for the company. PURE has transitioned to an all-remote work environment since 2019.

PURE Bioscience, Inc. (OTCQB: PURE) reported its Q2 and six-month results ended January 31, 2023. Net product sales decreased to $396,000 in Q2 from $415,000 in 2022, with a net loss of $1,060,000 compared to $702,000 in the same quarter last year. For the six months, sales totaled $863,000, down from $912,000, with losses rising to $2,053,000 versus $1,498,000 year-over-year. The company appointed Robert Bartlett as the new CEO on March 15, 2023, aiming to enhance revenue and redirect sales strategies.

PURE Bioscience reported its fiscal first quarter results for the period ending October 31, 2022, with net product sales of $467,000, down from $497,000 in the previous year. The company faced a net loss of $993,000, compared to $796,000 year-over-year. Despite these challenges, substantial adoption of the SDC-based antimicrobial in potato, snack food, and bakery sectors is noted, alongside growth in the dairy industry. New regional managers have been hired to enhance sales efforts across multiple industries. CEO Tom Y. Lee highlighted positive momentum and industry acceptance.